Synthetic Drug Prevention, Treatment, and Education Act

To amend the Public Health Service Act with respect to the prevention and treatment of the use of synthetic recreational drugs, and for other purposes. 1. Short title This Act may be cited as the Synthetic Drug Prevention, Treatment, and Education Act 2. Synthetic recreational drugs Title III of the Public Health Service Act is amended by inserting after section 317T of such Act ( 42 U.S.C. 247b–22 317U. Synthetic recreational drugs (a) Study Not later than 1 year after the date of enactment of the Synthetic Drug Prevention, Treatment, and Education Act, the Director of the Centers for Disease Control and Prevention (in this section referred to as the Director (1) complete a study on strategies for preventing and treating the use of synthetic recreational drugs (as identified pursuant to subsection (b)(3)), including best rehabilitation practices; and (2) submit a report to the Congress on the results of such study. (b) Database (1) In general The Secretary, in coordination with the Administrator of the Drug Enforcement Administration, shall establish and maintain a database of synthetic recreational drugs. (2) Availability The Secretary shall make the information in the database under paragraph (1) publicly available for use in preventing and treating the use of synthetic recreational drugs. (3) Identification of synthetic recreational drugs Beginning not later than 90 days after the date of the enactment of the Synthetic Drug Prevention, Treatment, and Education Act, for purposes of this section, the Secretary shall specify (and update as necessary) a list of substances, each of which shall satisfy the following criteria: (A) The substance is an analogue of a controlled substance (as defined in section 102 of the Controlled Substances Act). (B) The substance is not marketed as a drug (as defined in section 201 of the Federal Food, Drug, and Cosmetic Act). (C) The substance is determined by the Secretary to be marketed for recreational human use, irrespective of claims to the contrary in the labeling and promotion of the substance. Each substance identified on the most recent list specified by the Secretary pursuant to this paragraph is referred to in this section as a synthetic recreational drug (c) Cannabimimetic agents (1) Outreach campaign Not later than 1 year after the date of enactment of the Synthetic Drug Prevention, Treatment, and Education Act, the Director, in collaboration with the Assistant Secretary for Mental Health and Substance Use, the Director of the National Institute on Drug Abuse, the Director of the National Institutes of Health, and the Administrator of the Drug Enforcement Administration, shall develop and implement a national outreach campaign to educate law enforcement personnel, State and local agencies, health care professionals, community health organizations, parents, youth, and other community members about preventing and treating the use of cannabimimetic agents. (2) Grants (A) In general The Director may make grants to Federally-qualified health centers for programs to increase public awareness about, and prevent and treat, the use of cannabimimetic agents. (B) Partnership A Federally-qualified health center receiving a grant under subparagraph (A) for a program, may, to the extent such program is with respect to increasing awareness about, or preventing, the use of cannabimimetic agents, partner with a recipient of grant under section 1032 of the National Narcotics Leadership Act of 1988 ( 21 U.S.C. 1532 (C) Maximum amount The maximum amount of a grant under this section shall be $250,000. (D) Authorization of appropriations To carry out this paragraph, there is authorized to be appropriated $5,000,000 for the period of fiscal years 2018 through 2020. (d) Definitions In this section: (1) The term cannabimimetic agent (2) The term Federally-qualified health center .

Summary: Synthetic Drug Prevention, Treatment, and Education Act This bill amends the Public Health Service Act to require the Centers for Disease Control and Prevention (CDC) to study strategies for preventing and treating the use of synthetic recreational drugs, which are substances marketed for recreational use (regardless of claims to the contrary) that are analogous to a controlled substance and are not medications. The Department of Health and Human Services must coordinate with the Drug Enforcement Administration (DEA) to establish and maintain a database of synthetic recreational drugs. The database must be publicly available for use in preventing and treating the use of synthetic recreational drugs. The CDC, in collaboration with the Substance Abuse and Mental Health Services Administration, the National Institute on Drug Abuse, the National Institutes of Health, and the DEA, must develop and implement a national outreach campaign to educate law enforcement personnel, health care professionals, community members, and others about preventing and treating the use of substances similar to marijuana (cannabimimetic agents). The CDC may award grants to federally qualified health centers for public awareness programs regarding substances similar to marijuana. To carry out a public awareness program, grant recipients may partner with recipients of Drug-Free Communities Support Program grants.